ArticleCell biochemistry and biophysics2026
Synergistic Regeneration of Osteoporotic Bone Defects Using PBM, Stem Cells, and hMPMS Scaffolds Via the miR-21/RUNX2 Axis.
Article in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Postmenopausal osteoporosis compromises bone regeneration and elevates the risk of fracture nonunion, underscoring the necessity for more effective regenerative strategies. In this study, we investigated the regenerative efficacy of a combined therapy consisting of photobiomodulation (PBM), preconditioned adipose-derived stem cells (ADSCs), and human decellularized and mineralized placental matrix scaffolds (hDMPMS), in an ovariectomized induced osteoporosis (OVX) rat with critical-sized femoral defects (CSFD). We surgically created critical-size femoral defects (CSFD) in the distal metaphysis of the left and right femurs of thirty OVX rats. After inducing CSFD, hDMPMSs were implanted into each defect site. The animals were then randomly divided into five groups (n = 6 each group): (1) Control, (2) Scaffold, (3) Scaffold + Cell, (4) Scaffold + PBM (810 nm, 1.2 J/cm²), and (5) Scaffold + Cell + PBM. Eight weeks after treatment, the defect sites in the left femoral bone were harvested and subjected to mechanical compression testing, bone density measurement, as well as gene expression and histological analyses. One-way ANOVA revealed significant (P < 0.001) improvements in biomechanical strength, histological parameters, and bone density in all treatment groups compared to the control group. Among them, the combination treatment group (Cell + PBM) demonstrated the greatest enhancement across all evaluated parameters. Gene expression analysis revealed elevated levels of miR-21 and RUNX2 in all treatment groups, with the highest expression observed in the combination treatment group compared to the control group. The data indicate a substantial enhancement in bone repair for osteoporotic CSFDs treated with the combined therapy of hDMPMSs, PBM-preconditioned ADSCs, and PBM. This effect is likely mediated, at least in part, through modulation of bone remodeling processes and activation of the miR-21/RUNX2 osteogenic axis.
Indexed as
Identifiers
41251957What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.